If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen closely. In a new trial conducted by Eli Lilly, its tirzepatide injection for weight loss,

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time. Zepbound,